Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki w wieku 18 lat lub starsze
- •Potwierdzona diagnoza raka piersi na wczesnym etapie (typ HR+/HER2-, bez przerzutów odległych)
- •Przepisane leczenie abemaciklib zgodnie z charakterystyką produktu
- •Rozpoczęcie leczenia abemaciklib między 1 stycznia 2023 a 30 czerwca 2025
✗ Disqualifies
- •Zaawansowany lokalnie lub przerzutowy rak piersi
- •Pacjenci płci męskiej
- •Pacjenci, dla których abemaciklib jest przeciwwskazany
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- May 14, 2026
- Sex
- Female only
Locations (1)
Department of Obstetrics and Gynaecology, Uniklinikum Erlangen
Erlangen, Germany
Trial contact
Sponsor's study office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.